View Older Stories View More Recent Stories

Nov 10, 2022 07:00AM Seagen Names David R. Epstein as Chief Executive Officer and Director
Oct 27, 2022 04:02PM Seagen Reports Third Quarter 2022 Financial Results
Oct 6, 2022 08:00AM Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2022 Financial Results on October 27, 2022
Sep 27, 2022 08:03AM Zai Lab Limited (ZLAB) and Seagen (SGEN) Enter Collaboration and License Agreement for TIVDAK
Sep 27, 2022 08:00AM Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Sep 27, 2022 08:00AM Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Sep 27, 2022 08:00AM Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
Sep 26, 2022 08:02AM Seagen (SGEN), LAVA Therapeutics (LVTX) Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 26, 2022 08:00AM Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors
Sep 19, 2022 08:01AM Seagen (SGEN) Announces TUKYSAin Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
Sep 19, 2022 08:00AM Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer
Sep 12, 2022 08:56AM Seagen (SGEN), Merck (MRK) and Astellas Report Results of Trial Investigating PADCEV
Sep 12, 2022 08:55AM Astellas, Seagen and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
Sep 12, 2022 08:55AM Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urotheli
Sep 7, 2022 06:05PM Seagen to Highlight Research in Urothelial and Colorectal Cancers at 2022 European Society for Medical Oncology (ESMO) Congress
Sep 7, 2022 08:00AM Seagen to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
Aug 12, 2022 01:15PM Seagen (SGEN) Issues Statement on Outcome of Daiichi Sankyo Arbitration, Says "Disappointed"
Aug 12, 2022 01:14PM Seagen Statement on Outcome of Daiichi Sankyo Arbitration
Jul 28, 2022 04:02PM Seagen Reports Second Quarter 2022 Financial Results
Jul 26, 2022 05:54AM Seagen (SGEN) and Astellas Report Positive Topline Results For PADCEV with KEYTRUDA
Jul 26, 2022 04:00AM Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Jul 26, 2022 04:00AM Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
Jul 8, 2022 08:00AM Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2022 Financial Results on July 28, 2022
Jul 2, 2022 06:35AM Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positi
Jun 24, 2022 09:30AM Pre-Open Stock Movers 06/24: Zendesk Surges on Surprise Deal; LendingTree Falls on Lower Outlook (More...)
Jun 6, 2022 11:02AM Genmab (GMAB) and Seagen (SGEN) Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Jun 6, 2022 11:00AM Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Jun 6, 2022 11:00AM Seagen and Genmab Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Jun 6, 2022 11:00AM Genmab and Seagen Present Data from Tisotumab Vedotin (TIVDAK®) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting
Jun 3, 2022 03:13PM Seagen's (SGEN) ADCETRIS Plus Standard of Care Chemotherapy Demonstrates Superior EFS vs. Standard of Care Alone in Children and Young Adults with Previously Untreated High-Risk Hodgkin Lymphoma
Jun 3, 2022 03:12PM ADCETRIS® (brentuximab vedotin) Plus Standard of Care Chemotherapy Demonstrates Superior Event-Free Survival (EFS) vs. Standard of Care Alone in Children and Young Adults with Previously Untreated Hi
May 26, 2022 05:25PM Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022 05:00PM Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 05:00PM Genmab Announces Multiple Abstracts to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2022 08:00AM Seagen (SGEN) Reports Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA in Combination With Trastuzumab
May 23, 2022 08:00AM Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA® (tucatinib) in Combination With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
May 16, 2022 06:02AM Seagen (SGEN) Announces CEO Resignation
May 16, 2022 06:00AM Seagen Announces Resignation of President, Chairman & CEO Clay Siegall
May 9, 2022 06:01AM Seagen (SGEN) Announces CEO Takes Leave of Absence
May 9, 2022 06:00AM Seagen President, CEO and Chairman Clay Siegall Takes Leave of Absence
Apr 28, 2022 04:02PM Seagen Reports First Quarter 2022 Financial Results
Apr 28, 2022 08:00AM Seagen to Highlight Data from Expanding Oncology Portfolio at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 20, 2022 09:02AM Seagen (SGEN) to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
Apr 20, 2022 09:00AM Seagen Announces Plans to Expand Pacific Northwest Biomanufacturing Capacity to Support Growing Portfolio of Transformative Cancer Medicines
Apr 13, 2022 11:45AM European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
Apr 13, 2022 11:45AM European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
Apr 8, 2022 03:23PM Seagen (SGEN) Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
Apr 8, 2022 03:23PM Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
View More Recent Stories View Older Stories